Shenyang Xingqi Pharmaceutical Co Ltd (300573) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenyang Xingqi Pharmaceutical Co Ltd (300573) has a cash flow conversion efficiency ratio of 0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥268.97 Million ≈ $39.36 Million USD) by net assets (CN¥1.86 Billion ≈ $271.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300573 company net worth for the company's overall valuation and market capitalisation.
Shenyang Xingqi Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Shenyang Xingqi Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shenyang Xingqi Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenyang Xingqi Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Shenyang Xingqi Pharmaceutical Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
i-80 Gold Corp.
NYSE MKT:IAUX
|
-0.099x |
|
Dehua TB New Decoration Material Co Ltd
SHE:002043
|
-0.276x |
|
Gree Real Estate Co Ltd
SHG:600185
|
0.047x |
|
Walker & Dunlop Inc
NYSE:WD
|
-0.533x |
|
Autek China Inc
SHE:300595
|
0.031x |
|
Cronos Group Inc
TO:CRON
|
0.012x |
|
Aotecar New Energy Technology Co Ltd
SHE:002239
|
0.075x |
|
Nutex Health Inc
NASDAQ:NUTX
|
0.067x |
Annual Cash Flow Conversion Efficiency for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024. View Shenyang Xingqi Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.59 Billion ≈ $233.13 Million |
CN¥416.98 Million ≈ $61.02 Million |
0.262x | +39.28% |
| 2023-12-31 | CN¥1.69 Billion ≈ $247.29 Million |
CN¥317.57 Million ≈ $46.47 Million |
0.188x | +1.90% |
| 2022-12-31 | CN¥1.55 Billion ≈ $227.15 Million |
CN¥286.26 Million ≈ $41.89 Million |
0.184x | -19.23% |
| 2021-12-31 | CN¥1.34 Billion ≈ $196.74 Million |
CN¥306.96 Million ≈ $44.92 Million |
0.228x | +29.72% |
| 2020-12-31 | CN¥694.06 Million ≈ $101.56 Million |
CN¥122.16 Million ≈ $17.88 Million |
0.176x | +36.59% |
| 2019-12-31 | CN¥574.90 Million ≈ $84.13 Million |
CN¥74.08 Million ≈ $10.84 Million |
0.129x | +62.38% |
| 2018-12-31 | CN¥554.58 Million ≈ $81.15 Million |
CN¥44.01 Million ≈ $6.44 Million |
0.079x | +34.31% |
| 2017-12-31 | CN¥553.38 Million ≈ $80.98 Million |
CN¥32.70 Million ≈ $4.78 Million |
0.059x | +9.45% |
| 2016-12-31 | CN¥520.95 Million ≈ $76.23 Million |
CN¥28.12 Million ≈ $4.12 Million |
0.054x | -1.82% |
| 2015-12-31 | CN¥389.79 Million ≈ $57.04 Million |
CN¥21.43 Million ≈ $3.14 Million |
0.055x | +55.59% |
| 2014-12-31 | CN¥367.81 Million ≈ $53.82 Million |
CN¥13.00 Million ≈ $1.90 Million |
0.035x | +41.72% |
| 2013-12-31 | CN¥336.80 Million ≈ $49.28 Million |
CN¥8.40 Million ≈ $1.23 Million |
0.025x | -82.72% |
| 2012-12-31 | CN¥290.70 Million ≈ $42.54 Million |
CN¥41.96 Million ≈ $6.14 Million |
0.144x | +45.29% |
| 2011-12-31 | CN¥247.00 Million ≈ $36.14 Million |
CN¥24.54 Million ≈ $3.59 Million |
0.099x | -- |
About Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs… Read more